DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

被引：0
作者：
Nanda, Sarmistha
Shea, Martin J.
Schiff, Rachel
Osborne, C. Kent
Rimawi, Mothaffar
Fu, Xiaoyong
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P2-03-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-03-10
引用
收藏
页数：2
相关论文
共 50 条
  • [31] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Lim, Elgene
    Milioli, Heloisa H.
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine J.
    Chia, KeeMing
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne D.
    Swarbrick, Alex
    Caldon, Elizabeth C.
    Portman, Neil
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 110 - 110
  • [32] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Portman, Neil
    Milioli, Heloisa H.
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine J.
    Chia, Kee Ming
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne D.
    Swarbrick, Alex
    Caldon, C. Elizabeth
    Lim, Elgene
    [J]. BREAST CANCER RESEARCH, 2020, 22 (01)
  • [33] The Role of CDK4/6 Inhibitors in Breast Cancer
    Conleth G. Murphy
    [J]. Current Treatment Options in Oncology, 2019, 20
  • [34] CDK4/6 inhibitors in luminal breast cancer
    Gnant, Michael
    Steger, Guenther G.
    Bartsch, Rupert
    [J]. LANCET ONCOLOGY, 2015, 16 (01) : 2 - 3
  • [35] ESR1 mutations drive resistance to CDK4/6 inhibitors in ER plus Breast Cancer
    Chica-Parrado, M. Rosario
    Lin, Chang-Ching
    Jaeger, Ellen
    Harris, Michelle
    Guo, Lei
    Bikorimana, Emmanuel
    Napolitano, Fabiana
    Chao, Calvin
    Hanker, Ariella
    Arteaga, Carlos
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [36] The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
    Gomes, Ines
    Abreu, Catarina
    Costa, Luis
    Casimiro, Sandra
    [J]. CANCERS, 2023, 15 (19)
  • [37] Biomarker associated with response to CDK4/6 inhibitors in metastatic hormone receptor positive breast cancer
    Witkiewicz, Agnieszka
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [38] Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
    Pandey, Kamal
    An, Hee-Jung
    Kim, Seung Ki
    Lee, Seung Ah
    Kim, Sewha
    Lim, Sun Min
    Kim, Gun Min
    Sohn, Joohyuk
    Moon, Yong Wha
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (05) : 1179 - 1188
  • [39] The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER plus breast cancer
    Mao, Pingping
    Kusiel, Justin
    Cohen, Ofir
    Wagle, Nikhil
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [40] Molecular determinants of resistance to CDK4/6 inhibition in ER plus breast cancer
    Luo, F.
    Cowley, G.
    Garraway, L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S76 - S76
12345